U.S. market Closed. Opens in 3 hours 29 minutes

SGTX | Sigilon Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue12.94M9.60M13.37M14.15M4.64M
Cost of RevenueN/AN/AN/AN/AN/A
Gross Profit12.94M9.60M13.37M14.15M4.64M
Operating Expenses56.61M85.23M66.02M58.28M27.71M
Selling, General & Admin18.98M20.17M12.53M10.17M6.67M
Research & Development37.63M65.07M53.49M48.11M21.04M
Other Operating Expenses1.45M55.00K-89.00K-6.00K-81.00K
Operating Income-43.67M-75.64M-52.64M-44.12M-23.07M
Other Expenses / Income105.00K-1.68M-1.97M198.00K-99.00K
Before Tax Income-43.56M-77.31M-54.61M-43.92M-22.77M
Income Tax Expenses-105.00K925.00K259.00K644.00K599.00K
Net Income-43.46M-78.24M-54.87M-44.57M-22.77M
Interest Expenses2.29M1.99M1.20M650.00K289.00K
Basic Shares Outstanding32.41M2.45M2.42M1.62M1.21M
Diluted Shares Outstanding32.41M2.45M2.42M1.62M1.21M
EBITDA-41.27M-75.32M-52.42M-42.40M-22.08M
EBITDA Margin-318.84%-784.70%-391.95%-299.51%-476.26%
EBIT-41.27M-75.32M-53.41M-43.27M-21.88M
EBIT Margin-318.84%-784.70%-399.33%-305.72%-471.79%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙